Abstract
Triple-negative breast cancer (TNBC) remains difficult to treat because durable response is rarely achieved with conventional occupancy-driven inhibition. The central challenge is not simply a lack of actionable targets but a mismatch between TNBC's adaptive network biology and the limited depth of reversible node-by-node intervention. In this Perspective, we argue that the key medicinal chemistry question is not only which protein to engage, but which chemical modality best matches a given biological liability. We focus on metabolic coupling, epigenetic scaffold dependence, immune-stromal exclusion, and DNA damage response plasticity and discuss how these vulnerabilities motivate targeted degradation, molecular glues, covalent inhibition, rational polypharmacology, or prodrug design. Across these modalities, ternary-complex productivity, linker topology, warhead presentation, isoform selectivity, exposure control, and postwashout persistence often matter more than potency alone. Biological vulnerability defines the design problem, chemical modality defines the intervention logic, and durable network control defines success.
Funding Information
  • Yunnan Provincial Science and Technology Department (202502AA310002)
  • Double Thousand Plan of Jiangxi Province (S2021DQKJ2195)
  • Key Research and Development Program of Ningxia (2023BEG02010)
  • Key Research and Development Program of Ningxia (2026ZDYF0105)
  • National Natural Science Foundation of China (22267021)
  • National Natural Science Foundation of China (82473762)
  • Yunnan Fundamental Research Projects (202401BF070001-021)
  • Yunnan Fundamental Research Projects (202501AS070025)
  • Project of Innovative Research Team of Yunnan Province (202405AS350010)
  • Yunnan Health Training Project of High Level Talents (L-2025002)
  • Yunnan Academician Expert Workstation (202605AF350045)

This publication has 102 references indexed in Scilit: